Mortality outcomes and survival patterns of patients with myeloproliferative neoplasms in Malaysia

Yap, Yee Yee; Sathar, Jameela; Law, Kian Boon; Tan, Sen Mui; Lau, Ngee Siang; Ong, Tze San; Goh, Ai Sim; Chew, Teng Keat; Lim, Soo Min; Toh, See Guan; Sim, Xavier Yoon Han; Menon, Padmini; Guan, Yong Khee; Husin, Azlan; Wong, Lily Lee Lee; Chew, Lee Ping; Salleh, Sinari; Goh, Kim Yen; Leong, Kin Wah; Lim, Su Hong; Edmund, Syed Carlo; Tan, Jenq Tzong; Gan, Gin Gin; Yegappan, Subramaniam; Chang, Kian Meng

doi:10.1007/s10552-021-01521-2

Cited by 2 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,8 Patients with MPN have a shortened survival compared to the general population. [9][10][11][12] The crude annual incidence rate of MPN ranges from 1.15 to 4.99 per 100,000. 13 It is slightly more common in men than in women.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The personal impact of living with a myeloproliferative neoplasm

Eppingbroek,

Lechner,

Bakker

et al. 2024

Psycho-Oncology

View full text Add to dashboard Cite

ObjectiveThe aim of this study is to gain insight into the physical, psychological and social impact of having a myeloproliferative neoplasm (MPN), a rare type of cancer with an often chronic course.MethodsAn online survey was conducted among 455 Dutch MPN patients (62.7% female, age M 63) to explore the impact of the disease by measuring the MPN symptom burden (MPN‐SAF TSS) and quality of life (QoL) (EORTC QLQ‐C30) and its subscales within a hierarchical QoL model. We examined differences in MPN symptom burden and QoL in relation to sociodemographic and disease‐related factors. Hierarchical regression analysis was used to explain variances in QoL.ResultsMost patients (97%) experienced MPN‐related health complaints, with a significantly higher MPN symptom burden in women (M 31.50) compared to men (M 24.10). Regarding to fatigue and cognitive functioning MPN patients suffered more compared to a reference group of other cancers. MPN subtype or type of treatment did not show significant differences in MPN symptom burden or QoL. However, experiencing side effects, complications or comorbidities significantly negatively affected MPN symptom burden and QoL. 48.8% of patients reported that MPN affected their ability to work. The explained variance in overall QoL was 58%, most importantly by disease progression, comorbidities, MPN symptom burden and role, emotional and social functioning.ConclusionThis study revealed that having an MPN has a negative impact on several domains of QoL. Symptom assessment and support should be included in the healthcare management of MPN patients.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Current medical treatment focuses primarily on preventing thromboembolic complications and reducing the risk of the disease progression 1,8 . Patients with MPN have a shortened survival compared to the general population 9–12 . The crude annual incidence rate of MPN ranges from 1.15 to 4.99 per 100,000 13 .…”

Section: Introductionmentioning

confidence: 99%

The personal impact of living with a myeloproliferative neoplasm

Eppingbroek,

Lechner,

Bakker

et al. 2024

Psycho-Oncology

View full text Add to dashboard Cite

show abstract

Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives

Breccia,

Palandri,

Polverelli

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Myelofibrosis (MF) is a clonal disorder of hematopoietic stem cells characterized by altered bone marrow function and fibrosis. The aim of this narrative review is to report on the most recent epidemiologic data and to discuss features of MF and current strategies for the management of this condition in clinical practice. MF features covered by our review will include: characteristics of patients with MF; myeloproliferative and myelodepletive phenotypes; MF-associated thrombosis and bleeding; risk of infections; prefibrotic and overt PMF; secondary MF. Finally, we will discuss a few aspects of MF management in clinical practice and suggest strategies for its optimization and standardization. The focus of our paper is on Italy, but relevant data from other countries will also be reviewed.

show abstract

Mortality outcomes and survival patterns of patients with myeloproliferative neoplasms in Malaysia

Cited by 2 publications

References 37 publications

The personal impact of living with a myeloproliferative neoplasm

The personal impact of living with a myeloproliferative neoplasm

Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives

Contact Info

Product

Resources

About